| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics
|
Jun 03, 2026 | BUY |
Strong Buy
-15.4% avg upside
23 analysts
|
— | +13.7% |
|
PCVX
Vaxcyte
|
May 21, 2026 | BUY |
Strong Buy
+96.3% avg upside
15 analysts
|
— | +3.9% |
|
BIIB
Biogen
|
May 15, 2026 | BUY |
Strong Buy
+25.1% avg upside
51 analysts
|
— | +3.0% |
|
KLRA
Kailera Therapeutics, Inc.
|
May 12, 2026 | BUY |
Strong Buy
+96.0% avg upside
5 analysts
|
— | · |
|
ELAN
Elanco Animal Health
|
May 11, 2026 | BUY |
Strong Buy
+24.1% avg upside
18 analysts
|
— | +11.6% |
|
GILD
Gilead Sciences
|
May 07, 2026 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
— | -7.1% |
|
LLY
Eli Lilly & Co
|
May 04, 2026 | HOLD |
Strong Buy
-10.5% avg upside
47 analysts
|
— | +13.7% |
|
AMGN
Amgen
|
May 01, 2026 | BUY |
Buy
-11.6% avg upside
57 analysts
|
— | +6.3% |
|
TSE:BHC
Bausch Health Companies
|
Apr 30, 2026 | HOLD |
Buy
+783.6% avg upside
29 analysts
|
— | · |
|
PFE
Pfizer
|
Apr 27, 2026 | BUY |
Buy
+34.1% avg upside
45 analysts
|
— | -1.4% |
|
CNTA
Centessa Pharmaceuticals
|
Apr 20, 2026 | BUY |
Buy
-14.4% avg upside
19 analysts
|
— | +0.9% |
|
OGN
Organon
|
Apr 10, 2026 | HOLD |
Sell
+10.6% avg upside
9 analysts
|
— | +52.2% |
|
KOD
Kodiak Sciences
|
Mar 27, 2026 | BUY |
Buy
+37.6% avg upside
11 analysts
|
— | -3.5% |
|
AVIR
Atea Pharmaceuticals
|
Mar 09, 2026 | BUY |
Buy
+49.5% avg upside
6 analysts
|
$10.00
129.27% Upside
|
-27.0% |
|
RPRX
Royalty Pharma
|
Feb 12, 2026 | HOLD |
Strong Buy
+4.2% avg upside
15 analysts
|
— | +21.0% |
|
TEVA
Teva Pharmaceutical
|
Nov 26, 2025 | BUY |
Buy
-6.8% avg upside
39 analysts
|
— | +23.7% |
|
ALKS
Alkermes
|
Nov 12, 2025 | BUY |
Strong Buy
-17.5% avg upside
34 analysts
|
— | +44.4% |
|
MLYS
Mineralys Therapeutics, Inc.
|
Nov 11, 2025 | BUY |
Strong Buy
+82.2% avg upside
12 analysts
|
— | -46.7% |
|
RCUS
Arcus Biosciences
|
Oct 08, 2025 | BUY |
Strong Buy
+38.0% avg upside
20 analysts
|
— | +60.6% |
|
GUTS
Fractyl Health, Inc.
|
Sep 30, 2025 | BUY |
Strong Buy
+449.9% avg upside
6 analysts
|
— | -57.9% |
|
VOR
Vor Biopharma
|
May 12, 2025 | BUY |
Buy
+199.3% avg upside
17 analysts
|
— | +376.0% |
|
PRTA
Prothena
|
Feb 21, 2025 | BUY |
Buy
+160.9% avg upside
14 analysts
|
— | -42.0% |
|
MRK
Merck & Company
|
Feb 05, 2025 | BUY |
Strong Buy
+10.7% avg upside
43 analysts
|
— | +38.6% |
|
BLCO
Bausch + Lomb Corporation
|
Oct 15, 2024 | BUY |
Buy
+30.6% avg upside
19 analysts
|
— | -27.8% |
|
AMLX
Amylyx Pharmaceuticals Inc
|
Mar 08, 2024 | HOLD |
Strong Buy
+46.8% avg upside
13 analysts
|
— | +15.2% |
|
PHAT
Phathom Pharmaceuticals
|
May 11, 2023 | BUY |
Strong Buy
+163.5% avg upside
14 analysts
|
— | -27.8% |
|
LEGN
Legend Biotech
|
Nov 01, 2022 | BUY |
Strong Buy
+134.2% avg upside
27 analysts
|
— | +31.0% |
|
VTRS
Viatris
|
Dec 09, 2021 | BUY |
Buy
+48.2% avg upside
21 analysts
|
— | -10.8% |
|
JAZZ
Jazz Pharmaceuticals
|
Jan 28, 2021 | BUY |
Strong Buy
-1.8% avg upside
35 analysts
|
— | -16.6% |
|
PVLA
Palvella Therapeutics
|
Jul 20, 2020 | BUY |
Strong Buy
+45.4% avg upside
27 analysts
|
— | · |
|
MGNX
MacroGenics
|
Jun 04, 2019 | BUY |
Buy
+326.4% avg upside
25 analysts
|
— | +31.4% |
|
VRDN
Viridian Therapeutics
|
Mar 09, 2018 | BUY |
Strong Buy
+103.6% avg upside
32 analysts
|
— | -66.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.